Aptus Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Aptus Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,032	Closed	-$427K	–	906
2023 Q2	$427K	Sell	2,032 -37,099	-95%	-$7.38M	0.01%	338
2023 Q1	$7.9M	Buy	39,131 +38,154	+3,905%	+$8.65M	0.21%	97
2022 Q4	$213K	Sell	977 -17,186	-95%	-$3.75M	0.01%	467
2022 Q3	$3.58M	Sell	18,163 -7,676	-30%	-$1.66M	0.09%	138
2022 Q2	$5.53M	Buy	25,839 +1,323	+5%	+$323K	0.14%	96
2022 Q1	$6.96M	Buy	24,516 +6,737	+38%	+$2.08M	0.17%	81
2021 Q4	$6.7M	Buy	17,779 +4,312	+32%	+$1.68M	0.2%	69
2021 Q3	$5.56M	Buy	+13,467	New	+$5.59M	0.14%	76

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aptus Capital Advisors's CRL Position: Q3 2023 in Review

Aptus Capital Advisors sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 2,032 shares — an estimated $427K sold.

Aptus Capital Advisors first reported a position in CRL in Q3 2021 and held it in 8 quarters. The position peaked at $7.9M in Q1 2023. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Aptus Capital Advisors reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
Aptus Capital Advisors sold 2,032 Charles River Laboratories shares in Q3 2023, an estimated $427K.
Aptus Capital Advisors first reported a position in Charles River Laboratories in Q3 2021 and held it in 8 quarters.
Aptus Capital Advisors's Charles River Laboratories position peaked at $7.9M in Q1 2023.
621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Aptus Capital Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.